Navegar por autor "León Mateos, Luis Ángel"

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

2012- Barbazán, Jorge; Barbazán García, Jorge; Vieito Villar, María; Abalo Piñeiro, Alicia; Alonso Alconada, Lorena; [et al.]

Analysis of the expression of Wnt signaling ligands in metastatic renal cell carcinomas tissue samples

2012- Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; Firvida Perez, Jose Luis; León Mateos, Luis Ángel; [et al.]

Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis

2020- Rapado González, Oscar; Martinez-Reglero, C.; Salgado Barreira, Angel; Rodriguez-Fernandez, A.; Aguin Losada, Santiago; [et al.]

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

2013- León Mateos, Luis Ángel

C-Myc as a New Predictive Biomarker for Sunitinib in Metastatic Renal Clear Cell Carcinoma

2012- León Mateos, Luis Ángel

Calidad de vida después recidiva bioquímica en los pacientes con cáncer de próstata. ¿Cómo y cuánto viven los pacientes después de recidiva bioquímica?

2012- León Mateos, Luis Ángel; Gómez Caamaño, Antonio; Peleteiro Higuero, Paula; Carballo Castro, Ana María; Taboada Valladares, Maria Begoña; [et al.]

Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study)

2014- León Mateos, Luis Ángel

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

2013- Afonso Afonso, Francisco Javier; Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; León Mateos, Luis Ángel; [et al.]

Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results

2014- León Mateos, Luis Ángel; Campos Balea, Begoña

COST ASSESSMENT OF METASTATIC AND NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENT-MANAGEMENT IN SPAIN

2013- Gómez Veiga, Francisco; León Mateos, Luis Ángel

Cross-sectional observational study assessing the impact in daily clinical practice of the implementation of cooperative group (SOGUG) guidelines about management of targeted therapies in metastatic renal cell carcinoma (mRCC)(proTECT 2 Study)

2013- León Mateos, Luis Ángel; Lazaro Quintela, Martín; Vázquez Estévez, Sergio

CT perfusion in oncologic imaging: a useful tool?

2013- León Mateos, Luis Ángel; Gómez Caamaño, Antonio; Garrido Pumar, Miguel; Baleato Gonzalez, Sandra; García Figueiras, Roberto [et al.]

Cumplimiento estimado de los estándares de calidad propuestos en Cuidados Paliativos dentro de Unidades de Hospitalización de Oncología

2012- León Mateos, Luis Ángel; Cueva Bañuelos, Juan Fernando; Vázquez Rivera, Francisca; Barón Duarte, Francisco Javier; Martín De la Cruz, Myriam [et al.]

Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study

2020- Zapatero, A.; Gómez Caamaño, Antonio; Cabeza Rodriguez, M.; Muinelo Romay , Laura; Martin de Vidales, C.; [et al.]

Docetaxel in combination with Temsirolimus in patients with advanced castration resistant prostate cancer (CRPC): A phase II trial of the Spanish Oncology Genitourinary Group

2013- León Mateos, Luis Ángel

Early stage lung cancer treated only with surgery, impact of the 7th AJCC classification

2013- Vieito Villar, María; León Mateos, Luis Ángel; Candamio Folgar, Sonia; López López, Rafael; Vázquez Rivera, Francisca; [et al.]

Efficacy and Safety of Temsirolimus in Patients with Metastatic Renal Cell Carcinoma: Results from the Spanish Experience

2012- León Mateos, Luis Ángel

EGFR mutations and Glucose transporters expression, key factors for Maximal Standardized Uptake Value (maxSUV) 18F-FDG-PET values in lung adenocarcinomas

2011- Abdulkader Nallib, Ihab; León Mateos, Luis Ángel; Herranz Carnero, Michel; Pombo Pasín, Maria Carmen; Ruibal Morell, Alvaro; [et al.]

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel

2013- León Mateos, Luis Ángel

Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor

2012- Antón Aparicio, Luis Miguel; Anido Herranz, Urbano; Fernández Calvo, Ovidio; Firvida Perez, Jose Luis; León Mateos, Luis Ángel; [et al.]

Repositorio digital RUNA

Navegar por autor "León Mateos, Luis Ángel"

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer ﻿

Analysis of the expression of Wnt signaling ligands in metastatic renal cell carcinomas tissue samples ﻿

Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis ﻿

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study ﻿

C-Myc as a New Predictive Biomarker for Sunitinib in Metastatic Renal Clear Cell Carcinoma ﻿

Calidad de vida después recidiva bioquímica en los pacientes con cáncer de próstata. ¿Cómo y cuánto viven los pacientes después de recidiva bioquímica? ﻿

Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study) ﻿

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor ﻿

Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results ﻿

COST ASSESSMENT OF METASTATIC AND NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENT-MANAGEMENT IN SPAIN ﻿

Cross-sectional observational study assessing the impact in daily clinical practice of the implementation of cooperative group (SOGUG) guidelines about management of targeted therapies in metastatic renal cell carcinoma (mRCC)(proTECT 2 Study) ﻿

CT perfusion in oncologic imaging: a useful tool? ﻿

Cumplimiento estimado de los estándares de calidad propuestos en Cuidados Paliativos dentro de Unidades de Hospitalización de Oncología ﻿

Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study ﻿

Docetaxel in combination with Temsirolimus in patients with advanced castration resistant prostate cancer (CRPC): A phase II trial of the Spanish Oncology Genitourinary Group ﻿

Early stage lung cancer treated only with surgery, impact of the 7th AJCC classification ﻿

Efficacy and Safety of Temsirolimus in Patients with Metastatic Renal Cell Carcinoma: Results from the Spanish Experience ﻿

EGFR mutations and Glucose transporters expression, key factors for Maximal Standardized Uptake Value (maxSUV) 18F-FDG-PET values in lung adenocarcinomas ﻿

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel ﻿

Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor ﻿

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

Analysis of the expression of Wnt signaling ligands in metastatic renal cell carcinomas tissue samples

Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

C-Myc as a New Predictive Biomarker for Sunitinib in Metastatic Renal Clear Cell Carcinoma

Calidad de vida después recidiva bioquímica en los pacientes con cáncer de próstata. ¿Cómo y cuánto viven los pacientes después de recidiva bioquímica?

Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study)

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results

COST ASSESSMENT OF METASTATIC AND NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENT-MANAGEMENT IN SPAIN

Cross-sectional observational study assessing the impact in daily clinical practice of the implementation of cooperative group (SOGUG) guidelines about management of targeted therapies in metastatic renal cell carcinoma (mRCC)(proTECT 2 Study)

CT perfusion in oncologic imaging: a useful tool?

Cumplimiento estimado de los estándares de calidad propuestos en Cuidados Paliativos dentro de Unidades de Hospitalización de Oncología

Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study

Docetaxel in combination with Temsirolimus in patients with advanced castration resistant prostate cancer (CRPC): A phase II trial of the Spanish Oncology Genitourinary Group

Early stage lung cancer treated only with surgery, impact of the 7th AJCC classification

Efficacy and Safety of Temsirolimus in Patients with Metastatic Renal Cell Carcinoma: Results from the Spanish Experience

EGFR mutations and Glucose transporters expression, key factors for Maximal Standardized Uptake Value (maxSUV) 18F-FDG-PET values in lung adenocarcinomas

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel

Expression of Notch family members in stage IV renal cell carcinoma tumors: Notch1 as medium-risk prognosis factor